CRYO CELL INTERNATIONAL INC
For the period ended Feb 28, 2025. Filed Apr 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 28, 2025 · Filed Apr 14, 2025
CCEL$4.87-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| For the Three Months Ended | ||
|---|---|---|
| February 28, | February 29, | |
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income | $282,855 | $556,241 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization expense | 248,010 | 86,047 |
| Losses (gains) on marketable securities | 31,401 | (274,971) |
| Unrealized loss on interest rate swap contract | — | 45,288 |
| Compensatory element of stock options | 297,392 | 307,355 |
| Provision for doubtful accounts | 271,207 | 288,760 |
| Amortization of debt issuance costs | 5,246 | 5,348 |
| Amortization of operating lease right-of-use asset | 91,986 | 75,135 |
| Changes in assets and liabilities: | ||
| Accounts receivable | (174,098) | (439,413) |
| Prepaid expenses | (13,892) | 80,112 |
| Inventory | (34,577) | 49,856 |
| Other current assets | 18,359 | 11,640 |
| Deposits and other assets, net | (65,096) | (10,616) |
| Accounts payable | 735,107 | (931,007) |
| Accrued expenses | (1,473,052) | (1,253,911) |
| Operating lease liability | (94,564) | (54,682) |
| Other liabilities | — | (5,176) |
| Deferred revenue | 827,779 | 1,107,129 |
| Net cash from (used in) operating activities | 954,063 | (356,865) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (62,053) | (457,722) |
| Purchases of marketable securities | (599,611) | (743,811) |
| Sale of marketable securities | 374,180 | 860,484 |
| Net cash used in investing activities | (287,484) | (341,049) |
| Cash flows used in financing activities: | ||
| Treasury stock purchases | — | (170,376) |
| Repayments of note payable | (33,878) | (40,665) |
| Repayment of line of credit | (1,750,000) | (200,000) |
| Proceeds from line of credit | 2,800,000 | 950,000 |
| Dividends paid | (2,020,539) | — |
| Net cash (used in) provided by financing activities | (1,004,417) | 538,959 |
| Decrease in cash and cash equivalents | (337,838) | (158,955) |
| Cash and cash equivalents - beginning of period | 560,960 | 406,067 |
| Cash and cash equivalents - end of period | $223,122 | $247,112 |
| Supplemental investing activities: | ||
| Construction costs payable | $— | $219,748 |
| Duke license agreement payable | $— | $533,333 |
| Supplemental cash flow information: | ||
| Cash paid during the year for: | ||
| Interest | $485,413 | $443,829 |
| Income taxes | $— | $57,630 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.